In contrast, study peptides like BPC-157 and TB-500 appear to possess a much more favorable intrinsic safety profile in preclinical designs, but they carry the massive caveat of currently being unregulated and hugely at risk of high-quality control difficulties. This underscores our central thesis: with research peptides, the provider is as critica